References
- Ferrario CM, Richmond RS, Smith R, Levy P, Strawn WB, Kivlighn S. Renin-angiotensin system as a therapeutic target in managing atherosclerosis. Am J Ther, 2004;11(1):44-53. https://doi.org/10.1097/00045391-200401000-00010
- Weir MR, Dzau VJ. The renin-angiotensin -aldosterone system: a specific target for hypertension management. Am J Hypertens, 1999;12(12):205S-213S.
- Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R, Katagiri T. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens, 2002;16(12):857-863. https://doi.org/10.1038/sj.jhh.1001486
- Barrios V, Boccanelli A, Ewald S, Girerd X, Heagerty A, Krzesinski J, Lins R, Rodicio J, Stefenelli T, Woittiez A, Bhm M. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension:the OLMEBEST Study. Clin Drug Investig, 2007;27(8):545-558. https://doi.org/10.2165/00044011-200727080-00003
- Jiang J, Liu D, Hu P. Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations. Pharmazie, 2009;64(5): 323-326.
- Paster RZ, Snavely DB, Sweet AR, Draper RA, Goldberg AI, Soffer BA, Sweet CS. Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors. Clin Ther, 1998;20(5):978-989. https://doi.org/10.1016/S0149-2918(98)80079-9
- Gardner SF, Franks AM. Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann Pharmacother, 2003;37(1): 99-105. https://doi.org/10.1345/aph.1C197
- Brousil JA, Burke JM. Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther, 2003;25(4):1041-1055. https://doi.org/10.1016/S0149-2918(03)80066-8
- Li K, Liang J, Hu B, Qiu Y, Luo C, Jiang Y, Lin X, Yang N. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. Clin Ther, 2010;32(9): 1674-1680. https://doi.org/10.1016/j.clinthera.2010.08.004
- Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol, 1991;29(1):1-8.
- 식품의약품안전청. 고시 제2008-22호, 생물학적동 등성시험 기준, 식품의약품안전청, 서울, 2008.
- Administration. USFaD. Benicar (olmesartan medoxomil) tablets. http://www.fda.gov/Safety /MedWatch/SafetyInformation/ucm258490.htm [Online] (last visited on 20 Jan 2012).
- Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol, 2001;41(5):515-527. https://doi.org/10.1177/00912700122010393
- Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. Confidence interval criteria for assessment of dose proportionality. Pharm Res, 2000;17(10): 1278-1283. https://doi.org/10.1023/A:1026451721686
- U.S. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivanece Studies for Orally Administered Drug Products - General Considerations. Washington, DC., March 2003.
- von Bergmann K, Laeis P, Pchler K, Sudhop T, Schwocho LR, Gonzalez L. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl, 2001;19(1):S33-S40. https://doi.org/10.1097/00004872-200106001-00005
- Laeis P, Pchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl, 2001;19(1):S21-S32. https://doi.org/10.1097/00004872-200101000-00003
- Rohatagi S, Lee J, Shenouda M, Haworth S, Bathala MS, Allison M, Rubets I, Heyrman R, Noveck R, Salazar DE. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. J Clin Pharmacol, 2008;48(11):1309-1322. https://doi.org/10.1177/0091270008322176